Cancer Informatics In The Post Genomic Era

Cancer Informatics in Post-Genomic Era provides both the necessary methodology and practical information tools for analyzing data in the field of medical information science. This, of course, requires analytic tools. Those tools are garnered by developing and assessing methods and systems for the acquisition, processing, and interpretation of patient data, aided by scientific discovery. Key challenges in this field include integrating research and clinical care, sharing data, and establishing partnerships within and across sectors of patient diagnosis and treatment.

A comprehensive treatment of the role of bioinformatics in the emerging world of molecular medicine, for anyone involved in this new field

Omics is an emerging and exciting area in the field of science and medicine. Numerous promising developments have been elucidated using omics (including genomics, transcriptomics, epigenomics, proteomics, metabolomics, interactomics, cytomics and bioinformatics) in cancer research. The development of high-throughput technologies that permit the solution of deciphering cancer from higher dimensionality will provide a knowledge base which changes the face of cancer understanding and therapeutics. This is the first book to provide such a comprehensive coverage of a rapidly evolving area written by leading experts in the field of omics. It complies and details cutting-edge cancer research that covers the broad advances in the field and its application from cancer-associated gene discovery to drug target validation. It also highlights the potential of using integration approach for cancer research. This unique and timely book provides a thorough overview of developing omics, which will appeal to anyone involved in cancer research. It will be a useful reference book for graduate students of different subjects (medicine, biology, engineering, etc) and senior scientists interested in the fascinating area of advanced technologies in cancer research. Readership: This is a precious book for all types of readers – cancer researchers, oncologists, pathologists, biologists, clinical chemists, pharmacologists, pharmaceutical specialists, biostatisticians, and bioinformaticists who want to expand their knowledge in cancer research.

Breast cancer is the most common cancer in females that accounts for highest cancer specific deaths worldwide. In the last few decades research has proven that breast cancer can be treated if diagnosed at early stages and proper therapeutic strategy is adopted. Omics-based recent approaches have unveiled the molecular mechanism behind the breast tumorigenesis and aid in identification of next-generation molecular markers for early diagnosis, prognosis and even the effective targeted therapy. Significant development has taken place in the field of omics in breast cancer in the last decade. The most promising omics approaches and their outcomes in breast cancer have been presented in this book for the first time. The book covers omics technologies and budding fields such as breast cancer miRNA, lipidomics, epigenomics, proteomics, nutrigenomics, stem cell, pharmacogenomics and personalized medicine and many more along with conventional topics such as breast cancer management etc. It is a research-based reference book useful for clinician-scientists, researchers, geneticists and health care industries involved in various aspects of breast cancer. The book will also be useful for students of biomedicine, pathology and pharmacy.

The first edition of the Encyclopedia of Cancer and Society was published in 2007 and received a 2008 Editors’ Choice Award from Booklist. It served as a general, non-technical resource focusing on cancer from the perspective of the social and behavioral sciences, exploring social and economic impacts, the “business” of cancer, advertising of drugs and treatment centers, how behavior change could offer great potential for cancer prevention, environmental risks, food additives and regulation, the relation between race and ethnicity and cancer risk, socioeconomic status, controversies—both scientific and political—in cancer treatment and research, country-by-country entries on cancer around the world, and more. Given various developments in the field including new drug treatments, political controversies over use of the vaccines Gardasil and Cervarix with young girls to prevent cervical cancer, and unexpected upticks in the prevalence of adult smoking within the U.S. following decades of decline, the SAGE Encyclopedia of Cancer and Society, Second Edition serves as an updated and more current encyclopedia that addresses concerns pertaining to this topic. Key Features: · Approximately half of the 700 first-edition articles revised and updated · 30+ new entries covering new developments since 2006 · Signed entries with cross-references · Further Readings accompanied by pedagogical elements · New Reader’s Guide · Updated Chronology, Resource Guide, Glossary, and through new Index The SAGE Encyclopedia of Cancer and Society, Second Edition serves as a reliable and precise source for students and researchers with an interest in social and behavioral sciences and seeks to better understand the continuously evolving subject matter of cancer and society.

Six new chapters on vital topics of interest such as multilocus SNP genotyping (SNP chips), RNAi, ChIP-chip, and genomic tiling arrays New edition responds to reviewers' and users' desire for greater coverage—now the most useful handbook on the market! Practical, concise summary of everything about genomics and emerging technologies a busy physician or medical student should know Covers concepts and techniques that are in use in medicine now, as well as those on the cutting-edge of science relevant to medicine, from bioinformatics to DNA diagnostics and proteomics NEW: Includes chapter-end exercises, enhancing the utility of the new edition as a textbook NEW: PowerPoint slides of images available at instructor website

"In The Oncogenomics Handbook, a panel of internationally recognized researchers and clinicians provides an integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following that path, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development." --Résumé de l'éditeur.

Being a complex disease that affects millions of people world over, cancer research has assumed great significance. Translational cancer research transforms scientific discoveries in the laboratory into clinical application to reduce incidence of cancer, morbidity and mortality. On the other hand, personalized medicine in cancer is the concept that selection of a treatment should be tailored according to the individual patient’s specific genomic characteristics, including mutations, chromosomal aberrations, protein interactions, and SNPs, and even more, taking into account the inmume system, the metabolism and maybe in the next future also the microbiome.